TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...

Gilead Sciences (GILD) has been one of the most searched-for stocks ... While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' ...

Ligand Pharmaceuticals Incorporated today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will present at the Stifel 2024 Healthcare Conference in New York ...

Wolfe Research initiated coverage of Gilead (GILD) with an Outperform rating and $110 price target Published first on TheFly – the ...

Roughly a year ago, Gilead Sciences revealed that it was laying off about 7% of Kite Pharma’s workforce in a bid to refresh ...

Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often ...

More cuts are hitting Gilead’s cell therapy wing, including the closure of a Philadelphia office. A small number of additional job reductions are also being made across the broader company, according ...

Camlin Fine Sciences Ltd., incorporated in the year 1993, is a Small Cap company (having a market cap of Rs 1,825.20 Crore) operating in Chemicals sector. Camlin Fine Sciences Ltd. key ...